Japan Changes Rules On Drug Names, Study Codes In Sponsors' Trial Sites
Executive Summary
Japanese health ministry makes changes around the allowance of drug generic names and study codes in information provided by pharma companies on their websites for clinical studies, with the aims of improving transparency and facilitating patient participation.
You may also be interested in...
Eisai Digital Venture Theoria Plans Dementia Data Insights
A new digital health venture set up by Eisai plans to start operations in Japan from April 2024 with services related to cognitive impairment and dementia, in line with the Japanese firm's therapeutic advances in this area.
Otsuka Expands Ocular Gene Therapy Interests Through ShapeTX Deal
Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche.
Japan Takes New Steps To Build On Real-World Data Foundations
As Japan widens its window for the use of real-world data to support drug development though revision of the Next Generation Medical Infrastructure Act, the pharma industry is hoping for more regular inclusion in regulatory filings. A dedicated group within the PMDA shares its views on how the area is developing and practical measures being taken to drive RWD adoption.